New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …

Allogeneic hematopoietic cell transplant (allo‐HCT) provides the only potential route to long‐
term remission in patients diagnosed with blast phase transformation of myeloproliferative …

Poor graft function (PGF) is a life-threatening complication that occurs after transplantation
and has a poor prognosis. With the rapid development of haploidentical hematopoietic stem …

Hematopoietic cell transplantation (HCT) is a curative approach for myelofibrosis patients,
but relapse is a major cause of treatment failure. We investigated the effect of donor …

Secondary poor graft function (sPGF) increases the risk of life-threatening complications
after hematopoietic stem cell transplantation (HSCT). The incidence, clinical outcomes, and …

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative
treatment for myelofibrosis (MF). Relapse occurs in 10–30% and remains a major factor for …

Introduction Poor graft function (PGF) is a rare but serious complication of allogeneic
hematopoietic cell transplantation (alloHCT). Due to their hematopoietic supporting …

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation,
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …